Latest news with #NithyaBalasubramanian
Business Upturn
31-07-2025
- Business
- Business Upturn
IKS Health Reports Robust Q1 FY26 Results with 16% Year-over-Year Revenue Growth and 59% Year-over-Year PAT Increase
By Business Wire India Published on July 31, 2025, 23:11 IST Inventurus Knowledge Solutions Limited (NSE: IKS), a technology-enabled healthcare solutions provider, today announced strong growth in Q1 FY26. IKS Health, a care enablement platform focused on supporting physician enterprises primarily in the US, reported its financial results for the quarter ended June 30, 2025. Business Wire India Revenue growth in Q1 16% YoY in INR, 13% YoY in USD Q1 EBITDA up 36% YoY; 5% QoQ PAT up 59% YoY; 3% QoQ Inventurus Knowledge Solutions Limited (NSE: IKS), a technology-enabled healthcare solutions provider, today announced strong growth in Q1 FY26. IKS Health, a care enablement platform focused on supporting physician enterprises primarily in the US, reported its financial results for the quarter ended June 30, 2025. 'Our performance this quarter reflects the continued momentum in our business and the stickiness of our integrated tech-led care enablement platform built on strong client relationships, scalable solutions, and disciplined execution,' said Sachin K. Gupta, Founder & Global CEO, IKS Health. 'The sustained revenue growth at 16% and improvement of EBITDA margin for the combined entity to 32% demonstrates the impact of our technology-led care enablement platform and global delivery capabilities. As we move forward, our focus remains on deepening client value, investing in innovation, and scaling our platform to address the evolving needs of the healthcare ecosystem.' Nithya Balasubramanian, CFO, IKS Health, said, 'We delivered a strong financial performance in Q1 FY26, driven by consistent revenue growth and continued focus on operational efficiency. Our EBITDA margin improvement reflects disciplined cost management, scalability of our platform, and prudent capital allocation. As we move ahead, we remain committed to sustaining healthy margins while strategically investing in capabilities that drive long-term value creation.' Key Financial Highlights: Q1FY26 ended on June 30, 2025 Revenue at INR 7,401 million (15.6% YoY / + 2.2% QoQ growth) EBITDA at INR 2,378 million at 32.1% of revenue (36.3% YoY / +5.1% QoQ growth) PAT at INR 1,515 million at 20.5% of revenue (58.7% YoY / 2.5% QoQ growth) Adjusted PAT at INR1,682 million at 22.7% of revenue (51.4% YoY / 2.2% QoQ growth) Business Highlights: IKS Health continues to expand its reach and impact through strategic partnerships. The following highlights key collaborations, including both new alliances and the expansion of existing relationships, that demonstrate the company's commitment to driving financial outcomes, enabling growth, and enhancing clinical efficiencies for healthcare providers. Mission Community Hospital: New partnership to drive financial outcomes and accountability with end-to-end revenue cycle across the hospital acute care and ambulatory surgery spaces Bicycle Health: New partnership leveraging IKS to manage revenue cycle, enabling rapid growth and scale of the virtual network OrthoNY: Expanded partnership to introduce IKS Virtual Clinical Assistant at a growing specialty network to take on administrative tasks and support clinical efficiencies in addition to existing RCM services. A top 5 Health System: Expanded partnership for coding to drive revenue performance and mitigate operational inefficiencies. Recognition & Awards IKS Health received the below notable recognitions: ET HRWorld Exceptional Employee Experience – Large Scale Award BW CFO Finance & Strategy Excellence Awards Excellence in Mergers and Acquisitions Award – Gold (Organizational Category) Best Woman CFO, Nithya Balasubramanian (Individual Category) Safe Harbour Certain statements in this release concerning our future growth prospects may be seen as forward-looking statements, which involve a number of risks and uncertainties that could cause the actuals to differ materially from such statements. It is not possible to undertake to update any such statement that may have been made from time to time. Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Business Upturn
01-07-2025
- Business
- Business Upturn
IKS Health expands partnership with Western Washington Medical Group, invests in new management services organization
IKS Health has announced a strategic expansion of its partnership with Western Washington Medical Group (WWMG), a leading independent multispecialty healthcare provider in Washington State, USA. As part of this collaboration, IKS Health will make a significant investment in a newly established Management Services Organization (MSO) that will oversee all non-clinical operations for WWMG. The MSO will manage functions such as revenue cycle management, clinical documentation, HR, IT, and finance, while WWMG will retain control over all clinical operations. Advertisement The partnership aims to improve WWMG's performance across fee-for-service and value-based care models by reducing operational friction and enhancing financial sustainability and patient outcomes. WWMG will gain access to IKS Health's AI-enabled Care Enablement Platform, including advanced revenue cycle management tools, the Scribble Suite's ambient scribing solution, and a patient engagement hub designed to reduce no-shows and improve care communication. The investment will also help WWMG expand its physician base and primary care capacity. IKS Health CFO Nithya Balasubramanian said the investment reflects the company's strong conviction in the long-term potential of this partnership. CEO Sachin K. Gupta called the move a pivotal step in IKS Health's journey to lead strategic healthcare transformation. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Mint
16-05-2025
- Business
- Mint
US tailwinds, AI investments, to drive growth for IKS Health
Jhunjhunwala family-backed Inventurus Knowledge Solutions (IKS) aims to grow faster than the market in FY26 with more investments in artificial intelligence (AI), improving synergies with its acquired company AQuity Solutions and tailwinds in the US, CFO Nithya Balasubramanian told Mint in an interview. The Mumbai-based company offers tech-led healthcare solutions to hospital and clinic groups in the US. The sector's total addressable market in the US is $222 billion, of which $34 billion is outsourced. 'This outsourced market is growing at 12%, and we should be able to grow faster than the market…given the strength of [our] business model, we believe that we should be able to continue to grab market share," Balasubramanian said. IKS Health, which listed on the exchanges in December, posted its financial results for the quarter ended 31 March 2025, late on Thursday. The company reported strong revenue growth of 17% year-on-year in Q4FY25 to ₹724 crore, owing to a ramp-up of new clients. The company's profit after tax grew 133% y-o-y to ₹148 crore. It posted a healthy Ebitda margin of 31% during the quarter. Overall for FY25, it posted revenue of ₹2,664 crore, growing 47% y-o-y, with a margin of 30%. Also Read: Piramal Pharma to see muted CDMO growth on US jitters; strong recovery in FY27 'The last quarter saw five prominent client wins, including three platform deals, which gives us the confidence in our strategy of building the full breadth of our platform in a market that largely consists of point solutions companies," founder and CEO Sachin K. Gupta said in a release. Point solutions companies are also known as one-solution companies. The firm offers 16 features to clients, from optimized patient visit scheduling to revenue optimization solutions that help firms maximise revenues and more, and is targeting selling all of its features in platform deals to clients. Balasubramanian said there has been an uptick in interest and demand for this. She said that consumers are increasingly opting for IKS Health's full range of solutions rather than picking one or two and using other companies for the rest. Growth drivers Balasubramanian said the company will focus on AI investments in FY26, adding that it is trying to increase automation across all of its offerings. The company's total R&D spend is about 4.5-5.0% of its revenue. The Trump administration's focus on cutting healthcare costs is also a tailwind for the company, as clients look to reduce costs and improve efficiency. Also Read: Don't expect immediate impact of US tariff threat, price cuts on business, says Cipla head 'From our business perspective, these kinds of cost-cutting initiatives or efficiency-finding initiatives will be largely attainable for us because we are part of the solution," Balasubramanian said. 'Our platform actually allows provider organizations and health systems to be able to deliver their operations more efficiently," she said. The company has seen an uptick in interest and queries. 'The fact that we have been able to nudge more of our clients towards platform deals to me is also an indication that the conversations are shifting," she said. Additionally, the company has been able to improve synergies with its acquired entity, AQuity Solutions, in FY25. 'We have been able to transform AQuity's business model quite significantly," Subramanian said. AQuity, which offers clinical documentation, medical coding, and revenue integrity solutions, had 2-3 features as opposed to the 16 offered by IKS. AQuity, too, provides services to hospitals and healthcare chains like IKS Health. 'Most of them were delivered in an entirely human-led manner and also mostly onshore. From there, we have been able to deploy a combination of IKS's technology as well as change the mix from onshore to offshore," Subramanian said. AQuity was acquired by IKS in 2023 in a $200 million deal. Also Read: Biocon sees mid-teens revenue growth on biosimilars, generics push While the market for healthtech solutions and revenue cycle management (RCM) businesses is getting more competitive, Subramanian believes there is significant room for growth and that the company will be able to maintain its lead. 'We are differentiated because of the platform that we have to offer. Second, the kind of data that we have to be able to mature the tech faster than a newer player [and] the kind of deep relationships that we have," she said. Key takeaways
